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CD8+ T cells are essential effectors in antiviral immunity, recogniz-
ing short virus-derived peptides presented by MHC class I (pMHCI)
on the surface of infected cells. However, the fraction of viral
pMHCI on infected cells that are immunogenic has not been shown
for any virus. To approach this fundamental question, we used
peptide sequencing by high-resolution mass spectrometry to iden-
tify more than 170 vaccinia virus pMHCI presented on infected
mouse cells. Next, we screened each peptide for immunogenicity
in multiple virus-infected mice, revealing a wide range of immu-
nogenicities. A surprisingly high fraction (>80%) of pMHCI were
immunogenic in at least one infected mouse, and nearly 40%were
immunogenic across more than half of the mice screened. The high
number of peptides found to be immunogenic and the distribution
of responses across mice give us insight into the specificity of
antiviral CD8+ T cell responses.
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The recognition of peptide-MHC class I (pMHCI) complexesby CD8+ T cells plays an important role in mediating anti-
viral immunity. A comprehensive view of the specificity of these
antiviral responses requires an understanding of both the pMHCI
presented and the corresponding CD8+ T cell responses. This
requires systems where pMHCI can be identified and any CD8+
T cells elicited detected and quantified. The main approach in
mouse models, where quantification of responses is not confounded
by the numerous sources of diversity in human populations, has
focused around identification of immunogenic pMHCI (referred
to here as epitopes). For small viruses it is possible to generate
overlapping libraries of synthetic peptides that can be screened
to find many epitopes (1, 2). This approach is not feasible for
larger viruses, so epitope discovery for these has been done
largely by antigen expression screening and/or screening of syn-
thetic peptides predicted to bind MHCI (3–9). For vaccinia virus
(VACV), despite intensive efforts, the specificity of only around
half of the total antiviral CD8+ T cell response is known (10).
Further, without knowledge of the pMHCI presented during
infection it is unclear how these T cell specificities relate to the
targets available on infected cells. Indeed more generally, while
estimates have been made, it remains unknown for any virus the
fraction of viral pMHC specificities presented on infected cells
that are immunogenic (11).
Here we answer this question by bringing together high-
resolution mass spectrometry (MS) to profile a viral immuno-
peptidome with a mouse model where rigorous assessment of
immunogenicity is possible.
Results and Discussion
Comprehensive Identification of VACV-Derived pMHC. To generate a
comprehensive list of the VACV pMHCIs that might be pre-
sented during infection of C57BL/6 mice, we used DC2.4 cells as
the substrate because they have high expression levels of H-2b-
haplotype MHCI and high infection efficiency with VACV (12).
The cells were infected with VACV for 6 h because we have
demonstrated previously that presentation of epitopes from all
kinetic classes can be detected at this time (12, 13). H-2Kb and
Db molecules were individually isolated by immunoaffinity pu-
rification, and acid-eluted peptides were then analyzed by high-
resolution liquid chromatography–tandem mass spectrometry
(LC-MS/MS). Spectra were searched against the VACV
proteome. The distribution of the candidate VACV peptides
according to their statistical confidence shows a clustering of
sequences at the top, with around half having a confidence
of >95% (Fig. 1A). We applied an inclusive threshold of 50%
based on the appearance of two previously identified epitopes
with confidence levels as low as 70%. Subsequent screening of
the same data against combined mouse and VACV proteomes
flagged several ambiguous spectra that could be assigned as ei-
ther a VACV- or mouse-derived sequence, resulting in a list of
191 peptides (Dataset S1). Next, we validated this list in two
ways: First, the integrity of the MS data were tested by either
assessing the degree of similarity between spectra from peptides
eluted from infected cells and that of a corresponding synthetic
peptide (139 peptides) or through the sensitive detection method
of multiple reaction monitoring (MRM) of mock versus infected
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cells in combination with isotopically labeled heavy peptides (45
peptides) (14, 15). These paired spectra and MRMs were ana-
lyzed both by eye (e.g., Fig. 1 B and C) and more objectively by
calculating Pearson correlations between the sets of log-
intensities of the observed b and y ions (16) or computed dot-
products (dotp) for MRM (SI Appendix, Fig. S1A). Nearly 80%
of tested peptides had a statistically significant (P < 0.05) simi-
larity to the eluted peptide (Fig. 1D); of those that failed, some
were due to low signal intensity of the experimentally acquired
spectra. Indeed, four peptides with failed Pearson correlations
were detected with a rigorous dotp of 1 by the more sensitive
MRM assay. This process eliminated 19 potential false-positive
peptides, most likely of mouse origin, leaving 172 LC-MS/MS–
identified VACV-derived pMHCI. Second, we checked the dis-
tribution of lengths and the amino acids at predicted MHCI anchor
positions, finding the sets of peptides typical of ligands for H-2Kb
and Db (SI Appendix, Fig. S1 B and C). Taking this a step further we
measured the binding of these peptides to MHCI, which we note
correlated very well with predictions made with NetMHC 4 (SI
Appendix, Fig. S1D), and demonstrated that 84% of the VACV-
derived peptides bound MHCI with <500 nM affinity (Fig. 1E).
Finally, we note that our rate of discovery (73 and 97 for H-2Kb and
Db, respectively) was similar to that published for VACV in the
context of two human MHC allomorphs (110 and 64 peptides for
HLA-A2 and B7, respectively) (17).
Characteristics of VACV-Derived, MHCI-Presented Peptides. The 172
peptides identified by LC-MS/MS were spread across the VACV
proteome, being encoded by the four kinetic classes of viral
genes (18–20). Similar to other recent studies (4, 6, 17, 21), we
found at least one epitope in 40% of all VACV proteins (92 of
230 proteins), but some of these proteins were richer sources of
presented peptides (SI Appendix, Fig. S2A). In some proteins,
the multiple pMHC detected comprised sets of peptides that
were largely overlapping but with extensions at either the amino-
or carboxy-terminus (for example, proteins J4 and F5, respec-
tively; Dataset S1). In other cases, there were multiple non-
overlapping peptides from the same protein. Most of the proteins
here that are sources of multiple, nonoverlapping pMHC are
immunoprevalent, having multiple epitopes presented in the
context of several MHC allomorphs, e.g., A10, A3, A47, B8, and
J6 as defined by others (6, 17). Others are unique to this study,
e.g., A18, with five peptides and A23, A24, and A8, with three
peptides each. There is no obvious characteristic that links these
proteins, but understanding why they are so frequently presented
should help open one of the remaining black boxes in antigen
presentation: The selection of antigens and peptide precursors
that occurs before loading onto MHCI. To understand the fre-
quency of presentation across the proteome in a way that takes
into account the different sizes of viral proteins, we calculated
the number of presented peptides per 100 aa for each protein.
These proteins were then grouped according to kinetic class,
allowing an analysis of the role of expression time on pMHCI
display that was not confounded by the differing numbers and
sizes of genes in each class (Fig. 2B). This showed that there was
no significant difference in the frequency of epitope occurrence
by any kinetic class, suggesting that all are equally available
to the antigen presentation pathway (Fig. 2B). To extend this
analysis, we analyzed the abundance of pMHCI as inferred by
the precursor ion intensity and the number of times a given
peptide was identified by the mass spectrometer (i.e., spectral
counts). These methods are approximations, but we note that
they broadly correlate with each other across our data (SI Ap-
pendix, Fig. S2B). Intriguingly, the earliest class of genes was
found to be the source of significantly more pMHCI than the
later classes when normalized to their coding capacity (Fig. 2 C
and D), but this was not related to the affinity of these peptides
for MHC (SI Appendix, Fig. S2C). Looking at the individual
protein level, the distribution of presented peptides within a viral
protein shows that MHCI ligands are equally likely to be pro-
cessed from any part of an antigen (SI Appendix, Fig. S2D). The
start positions of the peptides were distributed along the entire
length of the protein, with the average sitting at almost the exact
midpoint of the protein, both for H-2Kb- and for Db-binding
peptides. Finally, VACV has been the subject of several studies
to identify MHCI-restricted epitopes and is already the best
characterized large virus in this regard, with >70 VACV-derived,
H-2b–restricted peptides or epitopes identified (Immune Epi-
tope Database, IEDB; ref. 22). Most of these peptides were
found first or confirmed in a single, landmark, proteome-wide
study that identified 49 epitopes from a library of ∼2,500 pre-
dicted pMHCI (4). This study set the benchmark for identification
of CD8+ T cell epitopes by prediction and screening and provides
a good dataset for comparison with our LC-MS/MS identified
peptides. The previously identified epitopes only partially over-
lapped with the MHCI ligands identified here (Fig. 2E). This
suggests limitations in all approaches. For our LC-MS/MS study,
Fig. 1. Identification of a viral immunopeptidome. Cells were infected with
VACV for 6 h, and MHCI-bound peptides were identified by LC-MS/MS. (A)
ProteinPilot confidence score for VACV peptide sequences. Known immuno-
genic peptides are in black. Number of peptides above 50 and 95% confidence
levels are shown at the top. (B) Example of a comparison between synthetic
(red, Lower) and eluted (black, Upper) peptide spectra. Dominant y and b ions
are indicated along with Pearson r correlation between spectra. (C) Example of
MRM detection of a peptide, showing the native (Upper) sequence only in
infected cells and spiked heavy peptide (Lower) in mock and infected samples.
Dot-product (dotp) of eluted detection is indicated. (D) Pearson r correlation
values (left axis) between synthetic and eluted spectra across 129 peptides.
Filled circles are peptides with a correlation P < 0.05; circles in green are eluted
peptides with ProteinPilot confidence >95%. The right axis shows MRM dotp
values for each peptide validated by MRM. (E) Distribution of binding affinities
of VACV peptides for MHCI.
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pMHCI found by prediction will be missed if they are not pre-
sented on DC2.4, which are only a model of the actual antigen-
presenting cell in vivo, or if they are only produced by cross-
presentation. Also there are limits to the sensitivity of LC-MS/MS
that mean that we will have missed some low-abundance pMHCI.
Overall, however, the striking result is that our LC-MS/MS
approach has more than tripled the number of pMHCI now
associated with VACV infection of C57BL/6 mice.
A High Fraction of VACV-Derived pMHC Are Immunogenic. Next we
screened the 172 candidate epitopes identified by LC-MS/MS for
immunogenicity. Synthetic peptides were used to stimulate
splenocytes from VACV-infected mice, with a readout of in-
tracellular IFN-γ production, which we have validated for
quantification of anti-VACV CD8+ T cells (23). Reactivity to
each peptide was tested eight times, and they were marked as
immunogenic in a test if the response exceeded the mean plus
three SDs of a set of negative controls, which received no pep-
tide (Fig. 3 A and B). The number of peptides that were found to
be immunogenic at least one time out of the eight tests was
surprisingly high (142/172; 83%). From this we conclude that the
vast majority of all viral pMHC have the potential to be immu-
nogenic across a population of infected hosts. Even if we were
more conservative and required a peptide to be positive in at
least two tests, the fraction of pMHC deemed immunogenic
would be almost 70%, which is also higher than previous esti-
mates (11). These data suggest that immunogenicity was not
binary, with peptides being found to be immunogenic in every
number of tests, from nil to eight. However, an examination of
the distribution of responses across the eight tests suggests a
more nuanced picture. In general, individual responses are dis-
tributed evenly around a mean that rises for peptides that are
found to be immunogenic in a greater number of mice. This can
be seen for selected examples (Fig. 3A) and also when the data
are plotted in aggregate for all mice and peptides (SI Appendix,
Fig. S3A). Indeed, the increase in population mean as pMHC are
positive in more mice can still be seen when values above the
threshold are removed (SI Appendix, Fig. S3B). This suggests
that our threshold limits the number of mice positive for pMHC
where responses are close to the limit of detection. It is possible
that adding further mice will find more peptides to be positive,
but we note that for the pMHC we have designated to be non-
immunogenic, the mean of all responses overlaps zero at the
95% confidence level. Having noted this general pattern, there
are examples of peptides (e.g., E1015–23; Fig. 3A) where the re-
sponses appear to be bimodally distributed, with the peptide
seemingly immunogenic in some mice, but not others. Perhaps
this occurs because particular T cell receptors are not available
in all mice. Further, we note all assays for immunogenicity are
subject to a threshold of detection. Altogether, we conclude that
from an experimental point of view, immunogenicity will typi-
cally be found to be broader across a population than within a
single individual, but in most cases this will reflect limits of de-
tection and not absolute immunogenicity. As a final note, we
tested mice by i.p. infection here, but immunogenicity of VACV
epitopes can be influenced by route of infection, dose, or viru-
lence of the strain used (24, 25).
The use of thresholds in individual mice also enables pMHC
to be divided into immunogenicity groups for the purpose of
further analyses. We have divided the pMHCI into three groups:
Nonimmunogenic, which were never positive; major epitopes,
which were positive in more than half of the mice (five to eight of
eight mice); and minor epitopes, which are the remaining pMHC
that were less frequently positive (one to four of eight mice).
Using this definition, we found 39 and 44% of pMHC detected
on VACV-infected cells to be major and minor epitopes, re-
spectively (Fig. 3B).
A Comprehensive Set of VACV CD8+ T Cell Epitopes. The peptides
detected by LC-MS/MS only partially overlapped the known H-
2b-restricted epitopes for VACV. So we extended the immuno-
genicity screen to the 46 VACV-derived H-2b–restricted pep-
tides/epitopes from the IEDB that were not found by LC-MS/
MS, in addition to one entirely unpublished and one more finely
mapped version of a published (26) epitope from other work in
our laboratories. Combining these with the set found by LC-MS/
MS gave 220 VACV peptides tested eight times, giving a number
of times positive and the average size of response for each
peptide. As expected from the above, the average size of the
CD8+ T cell response across this complete set of peptides cor-
related with the frequency with which a response was detected
(SI Appendix, Fig. S4A). This correlation was significant (r =
0.8219, P < 0.0001) by a Spearman rank test. Across the 220
pMHCI in this extended set, 84 were defined as major epitopes,
and most of these (67 peptides) were found by our LC-MS/MS
experiment (SI Appendix, Fig. S4B). By contrast, the large
Fig. 2. The protein sources of a viral immuno-
peptidome. (A) The number of H-2b–presented
peptides from each VACV protein. The viral pro-
teome is ordered by kinetic class and then position in
genome, from left to right. Gaps are proteins from
which no peptide was detected. (B) Peptide distri-
bution according to the kinetic class of source pro-
teins, normalized to protein length. (C and D)
Abundance of pMHC from MS precursor signal in-
tensity (C) and number of times each peptide was
sequenced by MS (D), according to the kinetic class
of source proteins, normalized to protein length. (E)
Comparison of number of peptides identified here
versus those identified previously. Epitopes identi-
fied in Moutaftsi et al. (4) and all others from the
IEDB are shown separately. Kruskal–Wallis multiple
comparison tests were used to determine signifi-
cance between all possible pairs in B–D; ns, not sig-
nificant, *P < 0.05, **P < 0.01, ***P < 0.001.
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predictive study by Moutaftsi et al. (4) identified less than half of
these major epitopes (35 peptides). The LC-MS/MS approach
also found most of the minor epitopes. We note that we were not
able to confirm the immunogenicity of all VACV peptides in the
IEDB, so some revision of the status of these peptides is required
(Dataset S1). Summed responses were used to show the fraction
of the total response contributed by specificities found by LC-
MS/MS compared with those already known (Fig. 3C). This in-
cluded some sets of peptides with largely overlapping sequences,
so to be conservative in our estimates of summed responses, we
assumed that these pMHC sets elicit responses from largely
overlapping sets of T cells. For this reason, only data from the
peptide in each set that gave the largest response were included
in summed responses. This revealed that our LC-MS/MS ap-
proach and the large predictive study of Moutaftsi et al. (4)
identified the epitope targets for ∼90 and 50% of the total anti-
VACV T cell specificities known thus far, respectively (Fig. 3C).
The limitations of our LC-MS/MS approach are noted above, but
we examined further why the predictive study failed to find so
many of the pMHC presented here. Three reasons were identi-
fied: (i) Length: The original predictions only considered 8- and
9-mer and 9- and 10-mer peptides for H-2Kb and Db, respec-
tively; (ii) Screening: Some peptides were predicted, but not
found to be immunogenic, in the earlier study; (iii) Prediction:
The original algorithms failed to rank some peptides highly
enough to include in testing. Each of these reasons account for
roughly a third of the peptides missed in the original study and
found by LC-MS/MS here (SI Appendix, Fig. S4 C and D). We
note that the original predictive study was done over a decade
ago, and significant advances in MHC-binding predictions have
occurred since then, which we expect will improve their accuracy.
Our data will be useful to objectively evaluate the performance
of newer algorithms and to identify weaknesses and refine
MHCI-binding predictions (e.g., as in SI Appendix, Fig. S1D).
Summing the responses to all nonoverlapping major and minor
epitopes shows that the vast majority of anti-VACV CD8+ T cells
are elicited by the major epitopes (Fig. 3D). Next, to estimate the
fraction of the total response to VACV that is contributed by the
newly expanded set of pMHCI, we compared the fraction of CD8+
T cells from spleens of acutely infected mice that were CD62L− and
Granzyme B+ with the summed response to the 90 most immu-
nogenic peptides (excluding overlapping peptides as noted above)
in these same mice (Fig. 3E). It is not possible to test all of the
peptides in a single mouse, but the 90 most immunogenic peptides
account for 95% of the response found by all of the immunogenic
peptides, so is a close estimate of the total now mapped. Using
CD62L and Granzyme B is a more accurate way to determine the
total anti-VACV CD8+ response than using virus-infected cells as
antigen-presenting cells and intracellular IFNγ as a readout, this
latter method underestimating the response by around 50% (10).
The comparison of these measures finds that these 90 pMHCI
account for around 70% of the total anti-VACV CD8+ T cell re-
sponse (Fig. 3E). This suggests that despite the depth of all of the
studies to date, further specificities remain to be defined. In addi-
tion to the limitations of using DC2.4 as the substrate for LC-MS/
MS, there may also be immunogenic peptides that have post-
translational modifications that we did not test, or come from
outside conventional ORFs, or that are spliced (27–31). Finally, the
25 most immunogenic peptides are shown in a hierarchy (SI Ap-
pendix, Fig. S4E), excluding any less immunogenic variants from
overlapping sets. This hierarchy includes four epitopes that we
have refined by identifying more immunogenic variants here (e.g.,
A8189–198 ITYRFYLINL, which is almost twice as immunogenic as
the previously defined A8189–196 ITYRFYLI), and eight peptides
for which no variants exist in the IEDB.
Factors Contributing to Immunogenicity. Noting the importance of
the major CD8+ T cell epitopes in the total response, we then
asked what factors were associated with these larger and more
prevalent responses, examining time of expression, amount
presented, and affinity of peptides for MHC.
First, the distribution of anti-VACV responses according to an-
tigen and arranged by kinetic class visually suggests that late viral
proteins were recognized by fewer CD8+ T cells (Fig. 4A) as pre-
viously suggested (32). We examined this more quantitatively in the
same way that we analyzed presentation on MHCI, by calculating
the occurrence of major epitopes (Fig. 4B) and the total size of the
response (Fig. 4C) per 100 aa for each viral protein. This allowed
an unbiased comparison of immunogenicity across the kinetic
classes. Immunogenicity was not significantly different across the
kinetic classes of genes as a whole, and the distribution of major
epitopes was not significantly different across the kinetic classes
(P = 0.2353, Fisher’s exact test). However, the distribution of highly
immunogenic proteins, defined as the top 10% by total size of
Fig. 3. The majority of members in a viral immunopeptidome are immu-
nogenic. Peptides were tested for reactivity against CD8+ T cells in spleens
from mice infected with VACV. Each peptide was tested in eight mice. (A)
The distribution of data from individual mice for a selection of 18 pMHC,
two to represent each possible number of times positive (as noted on top).
The dashed line represents the average of three times the SD of negative
controls across the eight mice, and closed circles are values that were above
the threshold for immunogenicity. (B) The distribution of pMHCI according
to the number of times that each was immunogenic out of eight tests. (C)
Comparison of the cumulative size of the response for VACV peptides
identified by LC-MS/MS here versus those identified previously. (D) Summed
size of the CD8+ T cell response of the major and minor peptides. (E) Com-
parison of the cumulative response to the top 90 most immunogenic VACV
epitopes against the total anti-VACV CD8+ T cell response (GzmB+, CD62L−)
7 d after infection. ***P = 0.0003 by paired t test.
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response, was significantly different (P = 0.04033, Fisher’s exact
test), with no late proteins in this category. Overall then, our data
support the notion that while late genes are equally likely to be a
source of pMHC on infected cells (Fig. 2), their epitopes are less
likely to be highly immunogenic.
Second, we investigated epitope abundance as inferred from
precursor ion intensities (Fig. 4D) and spectral counts (Fig. 4E).
On average, major pMHCI were identified by the mass spectrom-
eter significantly more times than minor, or nonimmunogenic
peptides. A similar trend was seen with precursor ion abundance,
but pair-wise comparisons between groups were not statistically
significant. Together these analyses suggest that abundance plays
some role in determining immunogenicity, but the evidence was
not especially strong. This conclusion is supported by the finding
that the E1.1 class of VACV genes was more abundantly pre-
sented (Fig. 2 C and D), but not more immunogenic (Fig. 4 B
and C) than other classes. Further, we note that a previous and
more rigorously quantitative study with a subset of these epitopes
found no correlation between dominance and immunogenicity (12).
Finally, we compared the binding affinity for MHCI of the
major and minor epitopes, focusing only on those peptides that
we identified by LC-MS/MS to ensure all were naturally pre-
sented (Fig. 4F). This found a very clear preference for high-
affinity MHCI binding among the major epitopes, with these
peptides having a significantly lower IC50 than minor epitopes
and nonimmunogenic pMHC (P < 0.0001 and P = 0.0005,
respectively, Kruskal–Wallis). While at face value this seems
to be an obvious finding, we emphasize that this analysis only
included peptides that were eluted from MHCI, and so all are
of sufficient affinity to be presented. Further, we ruled out a
role for confidence in the assignment of peptide identity in
the original LC-MS/MS data as a factor that may contribute to
the observed correlates with immunogenicity (SI Appendix,
Fig. S5 A and B).
Across these three factors, affinity for MHC was the most
rigorously associated with dominance, even in the set of peptides
we identified as being presented on infected cells. Therefore, we
speculate that the affinity of a peptide for MHC may have a
significance for CD8+ T cell immunity beyond making a pMHC
available at the cell surface.
Summary. To conclude, this study provides the largest resource of
LC-MS/MS–verified MHCI ligands along with their immunogenicity
for any viral infection model. Using this information it was found
that >80% of viral pMHC can be immunogenic across a set of in-
dividuals, a surprisingly high fraction. Immunogenicity was found to
be higher on a population basis than in individuals due to weak
epitopes not stimulating responses above the limit of detection in
all individuals. Finally, we found that while roles can be shown
for abundance and time of gene expression, major CD8+ T cell
responses are most strongly associated with high affinity for
MHCI, even among peptides that are known to be presented.
Materials and Methods
Detailed methods are provided in SI Appendix.
Viruses and Cell Lines. Sucrose cushion purified stocks VACV strain Western
Reserve (ATCC #VR1354) and DC2.4 cells (33) were used for LC-MS/MS
experiments.
Infection of Cells for LC-MS/MS. Many 1 × 108 DC2.4 cells (or 5 × 107 cells for
MRM validations) were infected at 10 plaque-forming units (PFU) per cell for
a total of 6 h at 37 °C, after which cells were centrifuged, media removed,
and the pellet snap frozen.
Mice and Infections. Specific pathogen-free female C57BL/6mice 8–16wk of age
were obtained from The Australian National University (ANU) Phenomics Fa-
cility (Canberra, Australia). Mice were housed, and experiments were done
according to the relevant ethical requirements and under an approval from the
ANU animal ethics and experimentation committee (approvals A2011.01,
A2013.37, and A2016.45). Mice were infected by the i.p. route with 1 × 106 PFU
of VACV in 200 μL of PBS. To test all peptides eight times, they were screened in
two main batches, so 16 mice were required for the main screen. Additional
mice were then used to fill data for some failed assays in the main screen.
Identification of pMHC by LC-MS/MS. VACV-infected cells were lysed, and
pMHCI complexes were purified (12). Briefly, cell lysates were cleared by
centrifugation, and pMHC immunoaffinity was purified on Sepharose beads
with anti-Kb or Db before elution with 10% acetic acid. The mixture of
peptides and MHC protein chains was fractionated on a reversed-phase C18
HPLC column. Peptide-containing fractions were analyzed on a 5600+
TripleTOF (SCIEX) mass spectrometer, operating in information-dependent ac-
quisition mode via an online Eksigent Tempo nanoLC autosampler (SCIEX) and
Eksigent cHiPLC nanoflex (SCIEX) system. For peptide identification, data were
searched by the Paragon algorithm of ProteinPilot (v4.5; SCIEX) against the
VACV strain WR proteome (2012–01; Uniprot). We initially searched against
the VACV proteome alone, making the following choices when analyzing the
Fig. 4. Factors associated with immunogenicity for
viral pMHC. (A) The cumulative size of CD8+ T cell
responses to each viral protein when ordered as in
Fig. 2A. Gaps are nonimmunogenic proteins. (B)
Distribution of major epitopes and (C) immunoge-
nicity of viral proteins across the kinetic classes, top
10% of immunogenic proteins are significantly re-
duced for late proteins (Fisher’s exact test, P =
0.04033). (D and E) Abundance of pMHC estimated
by precursor ion intensity (D) and number of times
sequenced by MS (E) across major, minor, and non-
immunogenic (Non) peptides. (F) Comparison of IC50
for major, minor, and nonimmunogenic peptides.
Kruskal–Wallis multiple comparison tests were used
to determine significance between all possible pairs in
D–F; *P < 0.05, ***P < 0.001, ****P < 0.0001.
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sequenced spectra. (i) Peptide FDR was ignored, instead allowing for a Pro-
teinPilot confidence score of as low as 50% to be acceptable for subsequent
testing (34); (ii) peptides that were detected as modified were included, but
considered as unmodified. To account for potential false-positives deriving
from mouse-derived pMHCI sequences, all spectra were sequenced against the
Mus musculus proteome (2018–08; Uniprot) appended to the above VACV
proteome. Spectra matching to mouse sequences in the latter search and VACV
sequences in the former search were excluded, subject to further validation.
Correlation of Synthetic Spectra with Observed Eluted Spectra. Synthetic
peptides were analyzed under LC-MS/MS conditions as above. MS2 spectra from
each synthetic peptide were then compared with that of the original identified
peptide from VACV-infected DC2.4 cells. Similarity between the spectra was
assessed manually and by taking the log10-intensities of identified b and y ions
and calculating their Pearson correlation coefficient and corresponding P value.
MRM. A mixture of each synthesized isotopic heavy peptide was spiked into
the acid eluate of immunoprecipitated pMHCI complexes from VACV- or
mock-infected cells before fractionation by RP-HPLC. Samples were assessed
for the presence of peptide by MRM, acquired on a QTRAP 5500 (SCIEX) mass
spectrometer equipped with an Eksigent Tempo nanoLC (SCIEX) autosampler
and an Eksigent cHiPLC nanoflex (SCIEX) and utilizing Analyst 1.6 (SCIEX)
software. MRM transitions are listed in Dataset S1. Data were analyzed in
Skyline 64-bit [v4.1.0.18169; MacCoss Laboratory (35)], with dot-product
values reported in Dataset S1.
Measurement of H-2b–Binding Affinity. Measurements of peptide affinity for
mouse class I H-2 Kb and Db molecules were based on the inhibition of
binding of high-affinity radiolabeled peptides to purified MHC molecules
and performed as detailed elsewhere (36). Each competitor peptide was
tested at six concentrations over a 105-fold range and in three or more
independent experiments. Measured IC50 values using this method are rea-
sonable approximations of true Kd (37, 38).
Quantification of Peptide-Specific CD8+ T Cells. Splenocytes frommice infected
with VACV 7 d previously were used to determine CD8+ T cell responses to
peptides (23–25). Briefly, 1 × 106 splenocytes were stimulated with peptides
at 10−6 M for a total of 4 h (with 5 μg/mL Brefeldin A for the last 3 h), before
being stained with monoclonal antibodies for surface CD8 and intracellular
IFNγ. Negative controls had no peptide added. The average plus three SDs
(of IFN-γ+ as a percent of CD8+) of negative controls was the threshold to
determine whether a particular peptide was immunogenic in a test. To es-
timate the size of the response to each peptide, the average from the
background wells was subtracted from values for each well. To determine
the total size of anti-VACV CD8+ T cell responses, splenocytes were stained
directly ex vivo for surface CD8 and CD62L and intracellular granzyme B.
Data Analysis and Statistics. As described above, mass spectra were analyzed
using ProteinPilot v4.5 (SCIEX). Raw mass spectra were analyzed using
Peakview v2.2 (SCIEX). MHC-binding predictions (IC50) were done using IEDB
analysis resources NetMHCcons (ver. 1.1) and NetMHC4.0 (39). Statistical
analyses of data were carried out in GraphPad Prism v7.01 or R studio using
the tests noted in the text and/or figure legends. For statistical tests, P < 0.05
was considered to be significant; unless noted otherwise, error bars or
graphs denote SD.
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